A case of autoimmune hemolytic anemia caused by thalidomide
10.12173/j.issn.1005-0698.202309109
- VernacularTitle:沙利度胺导致自身免疫性溶血性贫血1例
- Author:
Xiaoyan CHEN
1
;
Wenqiang KONG
;
Kun YANG
Author Information
1. 自贡市第一人民医院药剂科(四川 自贡 643000)
- Keywords:
Thalidomide;
Autoimmune hemolytic anemia;
Thalassemia
- From:
Chinese Journal of Pharmacoepidemiology
2024;33(5):591-594
- CountryChina
- Language:Chinese
-
Abstract:
This paper reported a 15-year-old girl with β-thalassemia major became dependent on blood transfusions from 6 months after birth whose blood transfusion needs increased with age.The girl started treatment with thalidomide at the age of 15.She became transfusion independent one month after starting thalidomide treatment,and her hemoglobin levels were maintained at 98-109 g·L-1.However,the girl subsequently developed symptoms of dizziness and fatigue in the 11th month of thalidomide treatment.Her hemoglobin was decreased and indirect antiglobulin test and direct antiglobulin test were positive.She was diagnosed with new onset autoimmune hemolytic anemia,which was considered to be related to thalidomide,and the association of adverse reactions was evaluated as"possible".Indirect antiglobulin test and direct antiglobulin test were negative after drug withdrawal and glucocorticoid therapy.Therefore,patients with thalassemia who are treated with thalidomide should be carefully monitored for the development of autoimmune hemolytic anemia.
